Market Intelligence, Clinical Progress, and High-Purity Reagents for Ion Channel Modulator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TRPC7 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | TRPC7 Lentivirus Premade Particles & Promise-ORF Full-length ORF (Accession: Q9HCX4), CMV promoter, Puromycin selection. High-titer (>1×10^8 TU/ml) for stable cell line construction. |
View TRPC7 Products |
| Antigen / Membrane Prep | TRPC7 Recombinant Protein (Partial ECD) & Membrane Target HEK293 expressed, native glycosylation. Purity >95%, Endotoxin <1 EU/μg. Sequence Verified. |
View TRPC7 Products |
| Benchmark Ab | Anti-TRPC7 Recombinant Antibody Sequence-verified. High purity (>95%). Endotoxin <1 EU/μg. For flow cytometry and immunoprecipitation. |
View TRPC7 Products |
| Validator | TRPC7 siRNA Set (3 unique sequences) For knockdown verification and target specificity controls in calcium flux and binding assays. |
View TRPC7 Products |
| Subfamily Panel A | TRPC3 High structural homology (≥70%). Essential for selectivity screening and counter-screening. |
View TRPC3 Products |
| Subfamily Panel B | TRPC6 Forms heterotetramers with TRPC7. Shared activation mechanisms, distinct disease profiles. |
View TRPC6 Products |
| Related Target | TRPM7 Distinct TRP family member; functional overlap in magnesium/calcium homeostasis. |
View TRPM7 Products |
| Related Target | ORAI1 Store-operated calcium entry partner; potential synthetic lethal interactions. |
View ORAI1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Full-length Functional Expression (Complex 6-TM membrane topology) | High-titer TRPC7 Lentivirus (Premade Particles) for stable integration. Preserves native glycosylation and post-translational modifications in mammalian HEK293 cells. |
| Subfamily Selectivity (TRPC3/TRPC6 homology >70%) | Ortholog Subfamily Panel: Human TRPC3, TRPC6 proteins available with >95% purity and Sequence Verified for cross-screening. |
| Species Cross-reactivity (Preclinical safety assessment) | Human, Mouse, Rat orthologs available. Sequence Verified identity for translational pharmacology. |
| Specificity Validation (Off-target liability) | TRPC7 siRNA Set included for genetic validation of assay signals. |
| False Positives & Baseline Control (Non-specific channel blockers) | Negative Control Lentivirus (Empty vector) available for establishing baseline in calcium flux assays. |
Live TRPC7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Inhibitor Research
- ➤ Ion Channel Mechanism Studies
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for TRPC7 therapeutics is intensifying. TRPC7 is a non-selective cation channel activated by diacylglycerol (DAG) and plays a fundamental role in calcium signaling anomalies associated with cardiovascular fibrosis, focal segmental glomerulosclerosis (FSGS), neurodegenerative conditions, and solid tumors. The target remains in early-stage discovery, with the therapeutic focus shifting from broad-spectrum pan-TRP inhibitors to isoform-selective small molecules, targeted protein degradation (PROTACs), and gene therapy strategies. As first-generation TRPC3/6 dual inhibitors face safety limitations (e.g., cardiac liability), the next wave of R&D is targeting TRPC7-selective modulation to capture differentiated safety and efficacy profiles in renal, cardiovascular, and CNS indications. The emergence of heteromeric TRPC3/6/7 complex modulation and conditional activation inhibitors is expected to drive the next breakthrough.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Preclinical biotech / Academic consortia | Cardiovascular Fibrosis, Hypertension, FSGS, Solid Tumors | Calcium Flux / Patch-Clamp using TRPC7 stable cell lines (Lentivirus-transduced HEK293) |
| Subfamily Selective Modulator | Specialized ion channel biotechs | FSGS, Diabetic Nephropathy, Neurodegeneration | TRPC3/6/7 Selectivity Panel (need ortholog & homolog cell lines) |
| Gene Therapy (Knockdown) | RNAi-focused platforms | Renal Fibrosis, Neurological Disorders | Validation via TRPC7 siRNA (positive control for knockdown efficiency) |
| Targeted Protein Degradation (PROTAC) | Preclinical Innovators | Refractory Cancers | Degradation tracking with specific antibodies and stable HEK293 lines |
| Monoclonal Antibodies | Discovery Stage Pharma | Cardiovascular Disease | Epitope binding using native conformation via Lentivirus lines |
| Biologic / Peptide (Exploratory) | Specialized research groups | Rare Ion Channelopathies | Cell-surface flow cytometry with full-length lentivirus expression |